ERIS Lifesciences Ltd
Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. Our focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors. Eris features amongst the Top 30 companies in the Indian Branded Formulations Market.
No of Eq. Shares:	13,57,80,653
Market Capital:	₹ 6,183	>	Enterprice Value:	₹ 6,133
Book Value:	₹ 95.45
Current Price:	₹ 455	>	Face Value:	₹ 1.00
52 Weel High/Low:	₹595.00/321.00
Stock P/E:	20.51	>	Industry P/E:	17.9
Dividend Yield:	0.64%	<	Earnings Yield:	5.44%
ROCE:	26.43%	<	ROE:	28.80%
Sales Growth:	18.05%	>	Profit Growth:	1.89%
Debt/Equity:	0.01
Debt:	₹ 12.14	Cr.
Contingent Liability:	₹ 0
Interest Coverage Ratio:	154.49
Current Ratio:	2.86
PEG Ratio:	0.62
Promoter Holdings:	55.55%		Mutual Funds:	10.51%
Pledged Percentage:	0.00%
Retail Shareholdings:	1.04%
Sales Growth			Profit Growth
10 Years:	0.00%	=	10 Years:	0.00%
5 Years:	14.06%	<	5 Years:	33.86%
3 Years:	18.05%	<	3 Years:	30.16%
TTM:	9.36%	>	TTM:	1.89%
Ques:	What is working for the Company?
	Company is Virtually Debt Free
	Company has good consistent profit growth of 33.86% over 5 years
	Company has a good return on equity (ROE) track record: 3 Years ROE 38.32%
	March 2020 Quarter Results are too good
	EPS is appreciable
	Reserve is 10 Time higher than its Debt
Ques:	What is Risk Involved in the Company?
	Net Cash Flow was quite negative
	DII Holdings has decreased by 1.05%